EGFR and non-small cell lung carcinoma: In the clinical trial CTONG 1104, our team and partners found that TCR Vβ5–6 Jβ2 − 1, TCR Vβ20 − 1 Jβ2 − 1, and TCR Vβ24 − 1 Jβ2 − 1 in NSCLC patients with an EGFR mutation were associated with good overall survival (OS) in the gefitinib group, while TCR Vβ29 − 1 Jβ2–7 was related to good OS in the conventional chemotherapy group [27].